The new hybrid molecule showed a potency superior to both HDAC inhibitor SAHA and Top1 inhibitor Irinotecan, increased antitumor activity and very high tolerability in in vivo human tumor models with respect to SAHA and Topotecan. The gene discussed is HDAC9; the disease is neoplasm.